Selecta Biosciences (SELB) Earns Buy Rating from Mizuho

Share on StockTwits

Mizuho reiterated their buy rating on shares of Selecta Biosciences (NASDAQ:SELB) in a research report sent to investors on Thursday. They currently have a $30.00 price target on the stock.

“We do not see quarterly earnings as the most meaningful indicator of value for development stage biotechs. Selecta will present data from the Phase 2 trial of SEL-212 for the five monthly dose cohorts at the Rheumatology (ACR) meeting on October 19-24, 2018. We think this is likely the biggest catalyst for the shares in 2018 and we view the probability of success as favorable. Phase 3 trial preparations are underway. A head-to-head trial with standard of care Krystexxa is also planned which we believe could be an important differentiator for SEL-212.”,” Mizuho’s analyst wrote.

A number of other research firms also recently issued reports on SELB. ValuEngine upgraded shares of Selecta Biosciences from a sell rating to a hold rating in a research report on Thursday, July 5th. Canaccord Genuity reiterated a buy rating and set a $40.00 target price on shares of Selecta Biosciences in a research report on Thursday, June 28th. Zacks Investment Research upgraded shares of Selecta Biosciences from a sell rating to a hold rating in a research report on Tuesday, May 15th. BidaskClub downgraded shares of Selecta Biosciences from a strong-buy rating to a buy rating in a research report on Wednesday, July 25th. Finally, Janney Montgomery Scott initiated coverage on shares of Selecta Biosciences in a research report on Wednesday, June 27th. They set a buy rating and a $33.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $28.25.

Shares of Selecta Biosciences stock traded up $0.27 during trading on Thursday, reaching $13.76. 69,922 shares of the company traded hands, compared to its average volume of 102,106. The company has a quick ratio of 7.20, a current ratio of 4.96 and a debt-to-equity ratio of 0.87. Selecta Biosciences has a 1-year low of $7.95 and a 1-year high of $24.02. The company has a market capitalization of $302.13 million, a PE ratio of -4.30 and a beta of -3.67.

Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.16). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 150.84%. sell-side analysts expect that Selecta Biosciences will post -3.13 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in SELB. Wells Fargo & Company MN increased its stake in Selecta Biosciences by 125.8% during the 4th quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock valued at $230,000 after purchasing an additional 13,086 shares in the last quarter. BlackRock Inc. increased its stake in Selecta Biosciences by 7.1% during the 4th quarter. BlackRock Inc. now owns 620,229 shares of the company’s stock valued at $6,085,000 after purchasing an additional 41,264 shares in the last quarter. Geode Capital Management LLC increased its stake in Selecta Biosciences by 12.1% during the 4th quarter. Geode Capital Management LLC now owns 92,803 shares of the company’s stock valued at $910,000 after purchasing an additional 9,988 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Selecta Biosciences during the 4th quarter valued at $289,000. Finally, Two Sigma Advisers LP bought a new stake in Selecta Biosciences during the 4th quarter valued at $143,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

See Also: What do I need to know about analyst ratings?

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply